Compare Amylx Pharmaceuticals Inc (AMLX) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs EPAM Systems Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while EPAM Systems Inc trades at $84.25 (market cap $4.38B). The key difference: EPAM Systems Inc is far larger — about 2.2× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | EPAM | |
|---|---|---|
Market Cap | $1.98B | $4.38B |
Sector | Health | Technology |
52-Week High | $18.70 | $221.40 |
52-Week Low | $7.64 | $76.04 |
Enterprise Value | $1.70B | $3.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
EPAM Systems trades at $83.89, down 3.9% in the last session, with a bearish technical signal from moving averages. The company maintains solid profitability with 29% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights EPAM's AI partnerships and upcoming Q2 2026 earnings release. Valuation metrics appear attractive with P/E of 12.05 and P/S of 0.84, well below sector averages.
The stock presents a compelling value opportunity with strong analyst support (65% buy ratings) and a $128.55 consensus price target representing 53% upside potential. Key risks include competitive pressures in IT services and recent net income margin compression from 9.61% in 2024 to 6.96% in 2025. The upcoming Q2 earnings report on July 6, 2026 will be critical for validating growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
